对于先前肝癌已治愈的丙型肝炎病毒（HCV）患者，开具直接作用抗病毒药物后，肿瘤复发风险会增加吗？ - Suppr

Is the risk of neoplastic recurrence increased after prescribing direct-acting antivirals for HCV patients whose HCC was previously cured?

作者信息

Zavaglia Claudio, Okolicsanyi Stefano, Cesarini Lucia, Mazzarelli Chiara, Pontecorvi Valerio, Ciaccio Antonio, Strazzabosco Mario, Belli Luca Saverio

机构信息

Department of Hepatology and Gastroenterology, Liver Unit, Niguarda Hospital, Milan, Italy.

Department of Medicine and Surgery, University of Milan-Bicocca, Milan, Italy; International Center for Digestive Health, University of Milan-Bicocca, Milan, Italy.

出版信息

J Hepatol. 2017 Jan;66(1):236-237. doi: 10.1016/j.jhep.2016.08.016. Epub 2016 Aug 31.

DOI:10.1016/j.jhep.2016.08.016

PMID:27592303

Abstract

摘要

相似文献

Is the risk of neoplastic recurrence increased after prescribing direct-acting antivirals for HCV patients whose HCC was previously cured?

J Hepatol. 2017 Jan;66(1):236-237. doi: 10.1016/j.jhep.2016.08.016. Epub 2016 Aug 31.

Direct-Acting Antivirals Decreased Tumor Recurrence After Initial Treatment of Hepatitis C Virus-Related Hepatocellular Carcinoma.

Dig Dis Sci. 2017 Oct;62(10):2932-2942. doi: 10.1007/s10620-017-4739-z. Epub 2017 Sep 7.

Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals.

Liver Transpl. 2017 Sep;23(9):1103-1112. doi: 10.1002/lt.24790.

Hepatocellular carcinoma recurrence in hepatitis C virus-related cirrhosis treated with direct-acting antivirals: a case-control study.

Eur J Gastroenterol Hepatol. 2018 Apr;30(4):368-375. doi: 10.1097/MEG.0000000000001082.

Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group.

PLoS One. 2018 Apr 16;13(4):e0194704. doi: 10.1371/journal.pone.0194704. eCollection 2018.

Hepatocellular Carcinoma Occurrence and Recurrence after Antiviral Treatment in HCV-Related Cirrhosis. Are Outcomes Different after Direct Antiviral Agents? A Review.

J Gastrointestin Liver Dis. 2017 Dec;26(4):403-410. doi: 10.15403/jgld.2014.1121.264.hcv.

Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C.

Liver Int. 2017 Aug;37(8):1122-1127. doi: 10.1111/liv.13456. Epub 2017 May 25.

Levels of Cytokines in Serum Associate With Development of Hepatocellular Carcinoma in Patients With HCV Infection Treated With Direct-Acting Antivirals.

Gastroenterology. 2018 Feb;154(3):515-517.e3. doi: 10.1053/j.gastro.2017.10.035. Epub 2017 Nov 2.

Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma.

J Hepatol. 2016 Oct;65(4):859-860. doi: 10.1016/j.jhep.2016.06.023. Epub 2016 Jul 5.

Reply to "Direct antiviral agents and risk for hepatocellular carcinoma (HCC) early recurrence: Much ado about nothing".

J Hepatol. 2016 Oct;65(4):864-865. doi: 10.1016/j.jhep.2016.05.036. Epub 2016 May 30.

引用本文的文献

Hepatocellular Carcinoma in Patients with Chronic Hepatitis C and Liver Cirrhosis Treated with DAA: A Focused Review.

J Clin Med. 2025 Feb 24;14(5):1505. doi: 10.3390/jcm14051505.

The Impact of Antiviral Therapy for Hepatitis C Virus on the Survival of Patients after Hepatocellular Carcinoma Treatment.

Intern Med. 2022;61(18):2721-2729. doi: 10.2169/internalmedicine.8456-21. Epub 2022 Sep 15.

Direct antiviral agents for HCV infection and hepatocellular carcinoma: facts and FADs.

Transl Cancer Res. 2019 Apr;8(Suppl 3):S223-S232. doi: 10.21037/tcr.2019.04.01.

Predicting Hepatocellular Carcinoma Risk in Patients with Chronic HCV Infection and a Sustained Virological Response to Direct-Acting Antivirals.

J Hepatocell Carcinoma. 2021 Jun 29;8:713-739. doi: 10.2147/JHC.S292139. eCollection 2021.

Tertiary Prevention of HCC in Chronic Hepatitis B or C Infected Patients.

Cancers (Basel). 2021 Apr 6;13(7):1729. doi: 10.3390/cancers13071729.

Timing of DAA Initiation After Curative Treatment and Its Relationship with the Recurrence of HCV-Related HCC.

J Hepatocell Carcinoma. 2020 Dec 1;7:347-360. doi: 10.2147/JHC.S279657. eCollection 2020.

Risk of Hepatocellular Carcinoma after HCV Clearance by Direct-Acting Antivirals Treatment Predictive Factors and Role of Epigenetics.

Cancers (Basel). 2020 May 26;12(6):1351. doi: 10.3390/cancers12061351.

Interferon Is Superior to Direct Acting Antiviral Therapy in Tertiary Prevention of Early Recurrence of Hepatocellular Carcinoma.

Cancers (Basel). 2019 Dec 19;12(1):23. doi: 10.3390/cancers12010023.

APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation.

Hepatol Int. 2019 Nov;13(6):649-661. doi: 10.1007/s12072-019-09988-7. Epub 2019 Sep 20.

No evidence for higher rates of hepatocellular carcinoma after direct-acting antiviral treatment: a meta-analysis.

Hepatoma Res. 2019;5. doi: 10.20517/2394-5079.2019.19. Epub 2019 Aug 7.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Is the risk of neoplastic recurrence increased after prescribing direct-acting antivirals for HCV patients whose HCC was previously cured?

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献